These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37517029)

  • 1. Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors.
    Schmidt L; Wang CA; Patel V; Davidson D; Kalirai S; Panda A; Seigel L
    Dermatol Ther (Heidelb); 2023 Sep; 13(9):2019-2030. PubMed ID: 37517029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database.
    Sbidian E; Billionnet C; Weill A; Maura G; Mezzarobba M
    Br J Dermatol; 2020 Mar; 182(3):690-697. PubMed ID: 31021438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.
    Armstrong A; Xia Q; John AR; Patel V; Seigel L
    Dermatol Ther (Heidelb); 2022 Sep; 12(9):2087-2103. PubMed ID: 35947341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis.
    Kaplan DL; Ung BL; Pelletier C; Udeze C; Khilfeh I; Tian M
    Clinicoecon Outcomes Res; 2020; 12():369-377. PubMed ID: 32765022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Burden of Comorbidities in Patients with Psoriasis in the USA.
    Wu JJ; Suryavanshi M; Davidson D; Patel V; Jain A; Seigel L
    Dermatol Ther (Heidelb); 2023 Jan; 13(1):207-219. PubMed ID: 36402940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between gastrointestinal events and persistence with osteoporosis therapy: analysis of administrative claims of a U.S. managed care population.
    Modi A; Siris S; Yang X; Fan CP; Sajjan S
    J Manag Care Spec Pharm; 2015 Jun; 21(6):499-506. PubMed ID: 26011551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization.
    Poulin Y; Beauchemin C; Royer C; Gaudreau AJ; Yim C; Liu FF; Lachaine J
    J Cutan Med Surg; 2020; 24(6):573-587. PubMed ID: 32597685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
    Blauvelt A; Shi N; Burge R; Somani N; Ridenour TL; Zhu B; Atiya B; Lew CR; Zimmerman NM; Murage MJ
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2133-2145. PubMed ID: 34652590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies.
    Thai S; Zhuo J; Zhong Y; Xia Q; Chen X; Bao Y; Dhanda D; Priya L; Wu JJ
    J Dermatolog Treat; 2023 Dec; 34(1):2176708. PubMed ID: 36794863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting.
    Kapniari E; Dalamaga M; Papadavid E
    Dermatol Ther; 2020 Nov; 33(6):e14168. PubMed ID: 32779293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience.
    Distel J; Cazzaniga S; Seyed Jafari SM; Emelianov V; Schlapbach C; Yawalkar N; Heidemeyer K
    Dermatology; 2022; 238(2):267-275. PubMed ID: 34091455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
    Hackshaw MD; Nagar SP; Parks DC; Miller LA
    J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
    Blauvelt A; Burge R; Gallo G; Charbonneau B; Malatestinic W; Zhu B; Wan F; Lockshin B
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):701-714. PubMed ID: 35220545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis.
    Wu JJ; Wang CA; Jobson G; Davidson D; Kalirai S; Zhu J; Suryavanshi M; Mittal M; Patel V; Seigel L
    J Dermatolog Treat; 2023 Dec; 34(1):2177095. PubMed ID: 36736349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.